A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy

INTRODUCTION: Apitegromab (SRK-015) is an anti-promyostatin monoclonal antibody under development to improve motor function in patients with spinal muscular atrophy, a rare neuromuscular disease. This phase 1 double-blind, placebo-controlled study assessed safety, pharmacokinetic parameters, pharmac...

Descripción completa

Detalles Bibliográficos
Autores principales: Barrett, Doreen, Bilic, Sanela, Chyung, Yung, Cote, Shaun M., Iarrobino, Ryan, Kacena, Katherine, Kalra, Ashish, Long, Kimberly, Nomikos, George, Place, Amy, Still, James Gordon, Vrishabhendra, Leela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189951/
https://www.ncbi.nlm.nih.gov/pubmed/33963971
http://dx.doi.org/10.1007/s12325-021-01757-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189951/
https://www.ncbi.nlm.nih.gov/pubmed/33963971
http://dx.doi.org/10.1007/s12325-021-01757-z

Ejemplares similares